Table 4.
Mechanisms leading to autoantibody-induced tissue injury in EBA.
Mechanism | Demonstrated by | Reference |
---|---|---|
Anti-COL7 IgG/A binding | Detection of anti-COL7 antibodies in patients, vast in vitro and in vivo (animal models) evidence | [125] |
Genetic control | Diverse susceptibility of different inbred mouse lines | [66] |
Neutrophils | Anti-Gr1 treatment completely protects from antibody transfer-induced EBA | [126] |
Fc-fragment mediated effects | (i) Anti-COL7 IgG, but not corresponding F(ab)2 fragments, induces EBA in vitro and in vivo (ii) Anti-COL7 IgY fails to induce experimental EBA in mice (iii) Enzymatic removal of terminal sugar residues has preventive and therapeutic effects in experimental EBA in mice |
[44, 60, 64, 104, 113] |
| ||
Cytokines | ||
(a) CXCL1 and CXCL2 | Blockade of the receptors has preventive and therapeutic effects in experimental EBA in mice | [127] |
(b) GM-CSF | Genetic and pharmacological GM-CSF inhibition has preventive and therapeutic effects in experimental EBA in mice | [128] |
(c) IL-6 | IL-6 has anti-inflammatory effects in antibody transfer-induced EBA; IL-6 induced IL-1ra, which in turn counteracts proinflammatory events triggered by IL-1 | [123] |
| ||
Complement activation | C5-deficient mice are completely protected from antibody transfer-induced EBA; partial protection is observed in C1q-, Factor B-, or C5aR-deficient mice | [44, 129, 130] |
| ||
Leukocyte extravasation | CD18-deficient mice are completely protected from antibody transfer-induced EBA | [126] |
| ||
Fc gamma RIIB | Fc gamma RIIB-deficient mice show a significantly increased cutaneous blistering in antibody transfer-induced EBA | [124] |
| ||
Fc gamma RIV | Fc gamma RIV-deficient mice are completely protected from antibody transfer-induced EBA | [124] |
| ||
Neutrophil activation | ||
(a) PI3K beta | PI3K beta-deficient mice are partially protected from antibody transfer-induced EBA | [61] |
(b) AKT | AKT impairs ROS released from immune omplex activated neutrophils | [131] |
(c) p38 | Pharmacologic inhibition of p38 phosphorylation partially protected from antibody transfer-induced EBA | [131] |
(d) ERK1/2 | Pharmacologic inhibition of ERK1/2 phosphorylation partially protected from antibody transfer-induced EBA | [131] |
| ||
ROS | Neutrophil cytosolic factor 1-deficient mice are completely protected from antibody transfer-induced EBA | [126] |
| ||
Elastase/Gelatinase B | Blockade of elastase or gelatinase B completely blocks dermal-epidermal separation | [132] |
| ||
Flii | Overexpression of Flightless I (Flii) increases dermal-epidermal blistering in antibody transfer-induced EBA, and blockade of Flii improves blistering | [133, 134] |